July 27, 2021 -- Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life science customers, totaling $1.5 billion over two years.
The investments include new sites in the U.S. and U.K., and expansion of existing facilities. The announcement follows five strategic acquisitions made by the companies in 2021 (Vanrx, Austar, GoSilico, Precision NanoSystems, and Intermountain Life Sciences) and is in addition to Cytiva's continuing capacity investments, which are estimated to be $500 million.
Specifically, the companies are investing the following:
The companies plan to hire 2,000 people over the next two years at the various facilities.
The investments also address key challenges highlighted in the Global Biopharma Resilience Index, including hiring and training talent, R&D collaboration, supply chain resilience, and manufacturing models.